目的 探討濟(jì)生腎氣丸聯(lián)合氯沙坦鉀片治療慢性腎小球腎炎的臨床療效。方法 選取2019年1月—2023年2月在安徽醫(yī)科大學(xué)附屬宿州醫(yī)院治療的88例慢性腎小球腎炎患者，隨機(jī)分為對照組（44例）和治療組（44例）。對照組口服氯沙坦鉀片，100 mg/次，1次/d。治療組患者在對照組基礎(chǔ)上口服濟(jì)生腎氣丸，1丸/次，3次/d。兩組患者均治療2個月。觀察兩組患者臨床療效，比較治療前后兩組患者腎功能指標(biāo)胱抑素C（CysC）、尿中性粒細(xì)胞明膠酶相關(guān)脂質(zhì)運載蛋白（NGAL）和尿視黃醇結(jié)合蛋白（RBP）水平，及炎癥指標(biāo)白細(xì)胞介素-6（IL-6）、γ干擾素（IFN-γ）、腫瘤壞死因子-α（TNF-α）水平。結(jié)果 治療后，治療組患者總有效率為90.91%，明顯高于對照組的75.00%（P＜0.05）。治療后，兩組患者血清CysC、尿NGAL、尿RBP水平及血清IL-6、IFN-γ、TNF-α水平均明顯降低（P＜0.05），且治療組患者降低幅度明顯大于對照組（P＜0.05）。結(jié)論 濟(jì)生腎氣丸聯(lián)合氯沙坦鉀片治療慢性腎小球腎炎具有較好的臨床療效，可有效改善患者的腎功能以及炎癥反應(yīng)。

Objective To explore the clinical efficacy of Jisheng Shenqi Pills and losartan potassium in treatment of chronic glomerulonephritis. Methods Patients (88 cases) with chronic glomerulonephritis in Suzhou Hospital of Anhui Medical University from January 2019 to February 2023 were randomly divided into control (44 cases) and treatment (44 cases) group. Patients in the control group were po administered with Losartan Potassium Tablets, 100 mg/time, once daily. Patients in the treatment group were po administered with Jisheng Shenqi Pills on the basis of the control group,1 pill/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical evaluation was evaluated, and the levels of renal function indicators CysC, NGAL and RBP, the levels of inflammatory indicators IL-6, IFN-γ and TNF-α in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 90.91%, which was significantly higher than that of the control group (75.00%, P < 0.05). After treatment, the levels of serum CysC, urinary NGAL, urinary RBP, and serum IL-6, IFN-γ and TNF-α levels in two groups were significantly decreased (P < 0.05), and the decrease in the treatment group was significantly higher than that in the control group (P < 0.05). Conclusion The combination of Jisheng Shenqi Pills and Losartan Potassium Tablets has good clinical efficacy in the treatment of chronic glomerulonephritis, which can effectively improve the renal function and inflammatory response.

R983

安徽省衛(wèi)生健康委科研項目（2019SEY020）